PMID- 25018644
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140714
LR  - 20211021
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 7
DP  - 2014
TI  - Exenatide extended-release: a once weekly treatment for patients with type 2 
      diabetes.
PG  - 229-39
LID - 10.2147/DMSO.S35331 [doi]
AB  - BACKGROUND: This article reviews the clinical efficacy, safety, and patient 
      outcomes literature on the first once weekly treatment for type 2 diabetes 
      mellitus (T2DM), exenatide extended-release (ER). METHODS: Relevant literature on 
      exenatide ER and T2DM was identified through PubMed database searches from 
      inception until April 2014. RESULTS: Exenatide ER is the first medication for the 
      treatment of T2DM dosed on a weekly schedule. Exenatide ER is a glucagon-like 
      peptide-1 (GLP-1) receptor agonist, the third to be approved in the US, and is 
      associated with a low risk of hypoglycemia, may result in weight loss, and has 
      proven to be a safe and effective treatment for T2DM. Exenatide ER reduces A1c 
      levels by decreasing fasting and postprandial hyperglycemia. The most common 
      adverse events are gastrointestinal in nature, which are lesser in frequency than 
      those observed with short-acting exenatide. Exenatide ER has been shown to be 
      more effective than exenatide twice daily and slightly less efficacious than 
      liraglutide. Exenatide ER is useful as monotherapy and in combination with other 
      oral antidiabetic drugs. CONCLUSION: Once weekly treatment options for diabetes 
      such as exenatide ER have the potential to offer substantial convenience for 
      patients who have high medication burden and poor medication adherence.
FAU - Mann, Katherine V
AU  - Mann KV
AD  - PharmD Consulting, LLC, Royal Oak, MD, USA.
FAU - Raskin, Philip
AU  - Raskin P
AD  - Department of Internal Medicine, Division of Endocrinology, the University of 
      Texas Southwestern Medical Center, Dallas, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140624
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC4075952
OTO - NOTNLM
OT  - GLP-1 receptor agonists
OT  - long-acting release
OT  - type 2 diabetes mellitus
EDAT- 2014/07/16 06:00
MHDA- 2014/07/16 06:01
PMCR- 2014/06/24
CRDT- 2014/07/15 06:00
PHST- 2014/07/15 06:00 [entrez]
PHST- 2014/07/16 06:00 [pubmed]
PHST- 2014/07/16 06:01 [medline]
PHST- 2014/06/24 00:00 [pmc-release]
AID - dmso-7-229 [pii]
AID - 10.2147/DMSO.S35331 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2014 Jun 24;7:229-39. doi: 10.2147/DMSO.S35331. 
      eCollection 2014.